The clinical effectiveness and cost-effectiveness of inhaler devices used in the routine management of chronic asthma in older children: A systematic review and economic evaluation

Health Technology Assessment

Volumn 6, Issue 5, 2002, Pages

  Peters, J ^a   Stevenson, M ^a   Beverley, C ^a   Lim, J N W ^a   Smith, S ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AEROCROM; ANTIASTHMATIC AGENT; ASMASAL; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE PLUS SALBUTAMOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGEN; CROMOGLYCATE DISODIUM; CROMOGLYCATE DISODIUM PLUS SALBUTAMOL; DOXOFYLLINE; FENOTEROL PLUS IPRATROPIUM BROMIDE; FILAIR; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; NEDOCROMIL SODIUM; NORFLURANE; OXITROPIUM BROMIDE; REPROTEROL; SALBUTAMOL; SALBUTAMOL SULFATE; SALMETEROL XINAFOATE; TERBUTALINE; UNCLASSIFIED DRUG;

ADOLESCENT; AEROSOL; ASTHMA; BIOMEDICAL TECHNOLOGY ASSESSMENT; CHILD; CHRONIC LUNG DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ECONOMIC ASPECT; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; INHALER; MEDICAL NEBULIZER; METERED DOSE INHALER; NATIONAL HEALTH SERVICE; POWDER INHALER; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; REVIEW; UNITED KINGDOM; CHRONIC DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; NEBULIZER; STANDARD; TREATMENT OUTCOME;

ADOLESCENT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; QUALITY-ADJUSTED LIFE YEARS; STATE MEDICINE; TREATMENT OUTCOME;

EID: 0036067909     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta6050     Document Type: Review

References (301)

1. Third International Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group
2. Inhaler use in children with asthma
3. Asthma treatment, perceived respiratory disability, and mortality
4. Questionnaire study of effect of sex and age on the prevalence of wheeze and asthma in adolescence
5. Prevalence of asthma symptoms, diagnosis, and treatment in 12-14 year old children across Great Britain (International Study of Asthma and Allergies in Childhood, ISAAC UK)
6. Health survey for England: The health of young people '95-'97
7. Trend in occurrence of asthma among children and young adults
8. British guidelines on asthma management: 1995 review and position statement
9. Risk factors and costs associated with an asthma attack
10. US National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the diagnosis and management of asthma
11. The burden of pediatric asthma
12. Early intervention in childhood asthma
13. Clinical issues in paediatric asthma
14. What are the goals of treating pediatric asthma?
15. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma
16. Clinical and cost effectiveness of inhaler devices for children with chronic asthma
17. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: A systematic review of the literature
18. Scottish Intercollegiate Guidelines Network (SIGN)
19. The use of inhaled corticosteroids in childhood asthma
20. The use of inhaled corticosteroids in adults with asthma
21. Inhaler devices for asthma
22. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone
23. Differing bioavailability of salbutamol MDIs
24. IMS Medical Data Index
25. Switching between metered dose inhalers (MDIs) and dry powder inhalers (DPIs) in airways disease: An analysis of age-specific rates using the general practice research database
26. What is new in asthma: New drug powder inhalers
27. Drug delivery
28. Future options for aerosol delivery to children
29. Metered dose inhaler: Past, present, and future
30. Budesonide inhalation powder: A review of its pharmacologic properties and role in the treatment of asthma
31. Inspiratory flow rates through a novel dry powder inhaler (Clickhaler) in paediatric patients with asthma
32. Comparison of inhaled corticosteroids
33. A meta-analysis of the effect of oral and inhaled corticosteroids on growth
34. Management of asthma in childhood
35. Asthma treatment and non compliance
36. Bandolier Drug watch - Large volume plastic spacers in asthma
37. Anatomy and physiology in delivery: Can we define our targets?
38. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
39. User's guides to the medical literature. IV: How to use an article about harm
40. Critical Appraisal Skills Programme (CASP)
41. Users' guides to the medical literature. XIII: How to use an article on economic analysis in clinical practice. A: Are the results of the study valid? Evidence-Based Medicine Working Group
42. Influence of spacer device on drug delivery to young children with asthma
43. Importance of training for correct Turbuhaler use in preschool children
44. Patient satisfaction with Easyhaler® compared with other inhalation systems in the treatment of asthma: A meta-analysis
45. Choosing the metered-dose inhaler spacer or holding chamber that matches the patient's need: Evidence that the specific drug being delivered is an important consideration
46. Lung deposition of inhaled drugs increases with age
47. A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration
48. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. UK Study Group
49. Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range
50. Inhalational drug delivery from seven different spacer devices
51. In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices
52. The output of budesonide from spacer devices under simulated breathing conditions
53. Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. German Study Group
54. Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device
55. Comparison of the protective effects of cromolyn sodium and nedocromil sodium in the treatment of exercise-induced asthma in children
56. Compliance with inhaled medications: The relationship between diary and electronic monitor
57. A systemic bioactivity comparison of double-strength and regular-strength beclomethasone dipropionate MDI formulations
58. Use of budesonide Turbuhaler in young children suspected of asthma
59. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma
60. A tube spacer to improve inhalation of drugs from pressurised aerosols
61. Development of a scale to measure children's metered-dose inhaler and spacer technique
62. Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications
63. Comparative efficacy and potency of ipratropium via Turbuhaler and pMDI in reversible airflow obstruction
64. The inhalation device influences lung deposition and bronchodilating effect of terbutaline
65. Proper use of the metered-dose inhaler in children utilizing a one-on-one teaching plan
66. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler
67. Comparison of handling and acceptability of two spacer devices in young children with asthma
68. The effects of salbutamol when given by 3 different methods of inhalation
69. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
70. Salbutamol administered through a new spacer device to prevent exercise induced asthma
71. Parental concern towards the use of inhaled therapy in children with chronic asthma
72. Asthma management in indigenous children of a remote community using an indigenous health model
73. A comparison of breathactuated and conventional metered dose inhaler inhalation techniques in elderly subjects
74. The choice of inhalers in adults and children over six
75. Clinical comparison of Gentle-Haler Actuator and AeroChamber spacer for metered dose inhaler (MDI) use by asthmatics
76. Factors affecting the efficiency of aerosol therapy with pressurised metered-dose inhalers through plastic spacers
77. Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device
78. Survey of unlicensed and off label drug use in paediatric wards in European countries
79. The efficacy and acceptability of two breath-actuated multi-dose powder inhalers in the treatment of chronic asthma
80. Reduction of morbidity in asthmatic children given a spacer device
81. Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate
82. Hydroflouroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose
83. A comparative study of the inhaled dry powder of salbutamol and fenoterol and their delivery systems
84. Bronchospasmolytic effects of salbutamol as powder inhalation in patients with reversible bronchial obstruction
85. Switch to non-CFC inhaled corticosteroids: A comparative efficacy study of HFA-BDP and CFC-BDP metered-dose inhalers
86. Effectiveness of inhaled bronchodilator delivery systems for elderly patients
87. Emitted doses of salbutamol pMDI from 5 different plastic spacer devices
88. Bronchodilating effect of terbutaline is more visible after administration via Turbohaler than PMDI or PMDI plus mental spacer device in school children with bronchial asthma
89. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler)
90. Drug delivery from holding chambers with attached face mask
91. In vitro comparison of beclomethasone and salbutamol metered-dose inhaler aerosols inhaled during pediatric tidal breathing from four valved holding chambers
92. In vitro comparison of salbutamol hydrofluoroalkane (Airomir) MDI aerosols inhaled during pediatric tidal breathing from 5 valved holding chambers
93. Comparison of two chamber devices in patients using a metered-dose inhaler with satisfatory technique
94. Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma
95. The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction
96. Overview of delivery system issues in pediatric asthma
97. Awareness of environmental issues and the acceptance of CFC-free inhalers
98. Adrenal suppression among asthmatic children receiving chronic therapy with inhaled corticosteroid with and without spacer device
99. Dry powder inhalation devices: Consumer perceptions of two new devices
100. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma
101. Results of the first US double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist
102. The Spacehaler for delivery of salbutamol: A comparison with the standard MDI plus Volumatic spacer device
103. Assessment of a new device (AeroChamber) for use with aerosol drugs in asthmatic children
104. A novel multidose powder inhaler. Salbutamol powder and aerosol give equal bronchodilation with equal doses
105. Reduction in patient timing errors using a breath-activated metered dose inhaler
106. Asthma: Addressing parents' fears and concerns
107. Comparison of conventional metered dose inhaler with breath actuated metered dose inhaler in elderly patients
108. Terbutaline from an ordinary pressurized aerosol or via a 750 ml spacer: A comparative long-term trial in two 4-week periods
109. An audit of inhaler technique among asthma patients of 34 general practitioners
110. Influence of inspiratory capacity on bronchodilation via Turbuhaler or pMDI in asthmatic children: A comparison
111. Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group
112. Correlates of asthma morbidity in primary care
113. A new multiple dose powder inhaler (DPI) in the treatment of asthma in children
114. Incorporating patients' preferences into medical decisions
115. Cost-effectiveness analysis of breath actuated metered dose inhalers
116. Use and acceptance of Ventolin Rotacaps and the Rotahaler in 1235 asthmatic patients
117. Long term effects of a tube extension on bronchodilator treatment with pressurised aerosol
118. The technology of metered-dose inhalers and treatment
119. Comparison of bronchodilating effects of two salbutamol dry powder inhalers in asthmatic patients
120. A comparison of Duovent Inhalets and Duovent Inhaler in asthmatic children
121. Inappropriate inhaler use: Assessment of use and patient preference of seven inhalation devices
122. Awareness of the ozone layer and acceptance of a new CFC-free metered dose inhaler among asthmatic patients
123. Cost effectiveness analysis of a dry powder inhaler (Turbuhaler) versus a pressurised metered dose inhaler in patients with asthma
124. Comparative lung delivery of salbutamol given by Turbuhaler and Diskus dry powder inhaler devices
125. Lung bioavailability of salbutamol via Turbuhaler and small volume metal spacer
126. Effects of treatment with formoterol on bronchoprotection against methacholine
127. Salbutamol doses inhaled via Turbuhaler give a better bronchodilating effect than when given via a pressurized metered dose inhaler
128. Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG)
129. Relative efficacy of three different inhalers containing salbutamol in patients with asthma
130. Inhaled versus oral steroids for adults with chronic asthma
131. Compliance in clinical trials of two nonbronchodilator, anti-asthma medications
132. Inhaled beclomethasone (BDP) with non-CFC propellant (HFA 134a) is equivalent to BDP-CFC for the treatment of asthma
133. In vitro performance testing of three small volume holding chambers under conditions that correspond with use by infants and small children
134. Comparison of the bronchodilator effect of inhaled salbutamol powder and pressurized salbutamol aerosol
135. Changes in asthmatic patients' symptoms and lifestyles on institution of inhaled budesonide therapy
136. Pediatric inspiratory flows through a novel multidose DPI
137. Comparison of the bronchodilator response to albuterol administered by the Optihaler, the AeroChamber, or by MDI alone
138. Improvement in drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique
139. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols
140. Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler
141. Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children
142. Domiciliary comparison of terbutaline treatment by MDI with and without conical spacer in severe and moderately severe chronic asthma
143. Comparison of Bricanyl Turbuhaler and Ventolin Rotahaler in children with asthma
144. Terbutaline in asthmatic children - A comparison of the conventional "inhaler" and "spacer" methods of administration
145. Treatment of asthmatic children with budesonide from a Turbohaler and a MDI with a Nebuhaler
146. Budesonide treatment of moderate and severe asthma in children: A dose response study
147. Use of different inhalation devices in children
148. Aerosol treatment of bronchoconstriction in children with or without tube spacer
149. Treatment of bronchoconstriction in children with a breath-actuated and a conventional metered dose inhaler
150. How to use a Rotahaler
151. Influence of inspiratory flow rate upon the effect of a Turbuhaler
152. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International Study Group
153. An assessment of acceptability of two breath-actuated corticosteroid inhalers: Comparison of Turbuhaler and Diskhaler
154. Washing plastic spacers in household detergent reduced electrostatic charge and greatly improves delivery
155. The problems of treating adolescent asthma: What are the alternatives to inhaled therapy?
156. Effect of different inhaled bronchodilators on recovery from methacholine-induced bronchoconstriction in asthmatic children
157. Measuring adherence to medical treatments in childhood chronic illness: Considering multiple methods and sources of information
158. The accuracy of asthmatic children's drug usage records using two breath-actuated dry-powder inhalers
159. Effect of administration technique on bronchodilator response to fenoterol in a metered-dose inhaler
160. An assessment of a new breath actuated inhaler device in acutely wheezy children
161. Economic appraisal of asthma and COPD care: A literature review 1980-1991
162. Evaluating the outcome of two teaching methods of breath actuated inhaler in an inner city asthma clinic
163. Equivalence of salbutamol 200 microg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Eastern European Study Group
164. Paper spacers coupled to metered dose inhalers in family practice
165. What are minimal important changes for asthma measures in a clinical trial?
166. A device for overcoming discoordination with metered-dose inhalers
167. Patient perception of the Diskus inhaler: A comparison with the Turbuhaler inhaler
168. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics
169. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma
170. Characteristics of children hospitalized with mild to moderately severe asthma
171. Maximum bronchodilator effect of pirbuterol and procaterol administered as sprays with and without an AeroChamber
172. Noncompliance with asthma therapy - Are there solutions?
173. Dose response to inhaled terbutaline powder and peak inspiratory flow through Turbuhaler in children with mild to moderate asthma
174. Evaluation of a new spacer device for drug inhalation
175. Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction
176. Probability of particle and salbutamol deposition in the respiratory tract: Comparison between MDI and Autohaler
177. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol
178. Lung deposition of budesonide from Turbohaler is twice that from a pressurised metered-dose inhaler P-MDI
179. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurised metered dose inhaler to patients with mild to moderate asthma. French study group
180. Teaching inhalation techniques to asthmatic children: A randomized clinical trial
181. MDI add-on devices: Is the inhaled mass drug dependent on the size of the infant?
182. In vitro and in vivo deposition of drug particles inhaled from pressurized aerosol and dry powder inhaler
183. Asthma treatment and non-compliance
184. The therapeutic equivalent and acceptability of two multidose powder inhalers in the treatment of asthma
185. Electrostatic charge on a plastic spacer device influences the delivery of salbutamol
186. Lung deposition of budesonide from Turbuhaler in asthmatic children
187. High-percentage lung delivery in children from detergent-treated spacers
188. Reducing electrostatic charge on spacer devices and bronchodilator response
189. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants
190. Ease of handling and clinical efficacy of fluticasone propionate Accuhaler/Diskus inhaler compared with the Turbohaler inhaler in paediatric patients. UK Study Group
191. Inhaled terbutaline administered via a spacer fully prevents exercise-induced asthma in young asthmatic subjects: A double-blind randomised placebo-controlled study
192. Comparison of the effects on lung function of two methods of bronchodilator administration
193. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution
194. Home-made spacers for bronchodilator therapy in children with acute asthma: A randomised trial
195. The efficacy of alternative spacer devices for delivery of aerosol therapy to children with asthma
196. 1 of salbutamol administered with an AeroChamber, spacer and metered dose inhaler
197. Maximum inspiratory flows in healthy children and asthmatics 4 to 8 years old. The implications for the inhalation of drugs in powder form
198. Peak expiratory flow in healthy children aged 9-14 years through two inhalers, using two different models of a new portable apparatus
199. Inhalation technique in patients with chronic respiratory diseases
200. Changes in metered dose inhaler propellants
201. Bronchodilator effect of inhaled terbutaline in asthmatic children with and without a tube spacer
202. Effect of spacer device on bronchodilation in asthmatic children
203. Inhalation spacer devices in childhood asthma: Is utilization easy?
204. Round Table: Severe asthma in pediatrics: Diagnosis and prognosis
205. Comparison of the efficacy, tolerance and acceptability of beclomethasone dipropionate delivered by Prolair Autohaler™ versus a standard aerosol doser linked to a spacer device in children
206. Inhalation therapy in children. Delivery systems and inhalation technique in children over 5 years (and II)
207. Evaluation of the ability of asthmatic children to use a breath-actuated pressurized inhaler
208. Sodium cromoglycate via inhaler and Autohaler
209. Albuterol treatment for children with asthma: A comparison of inhaled powder and aerosol
210. Albuterol aerosol versus Rotacaps in exercise-induced bronchospasm
211. Treatment of asthma in pre-school children with inhalation of terbutaline in Turbuhaler compared with Nebuhaler
212. Comparison of a new multidose powder inhaler with a pressurized aerosol in children with asthma
213. A double-blind comparison between a new multidose powder inhaler (Turbuhaler) and metered dose inhaler in children with asthma
214. Comparison of inhaled terbutaline administered by either the Turbuhaler dry powder inhaler or a metered-dose inhaler with spacer in preschool children
215. A comparison of terbutaline inhaled by Turbuhaler and by a chlorofluorocarbon (CFC) inhaler in children with exercise-induced asthma
216. A comparison of the bronchodilatory effect of 50 and 100 microg salbutamol via Turbuhaler and 100 microg salbutamol via pressurized metered dose inhaler in children with stable asthma
217. A low cost spacer device used for asthma treatment in a Calcutta street clinic to improve efficacy of metered dose inhalers
218. Bronchodilator effect of salbutamol via the Volumatic in children
219. Terbutaline by metered-dose inhaler: Conventional inhaler versus tube spacer for children with asthma
220. Use of tube spacer to improve the efficacy of MDI in asthmatic children
221. Childhood asthma: Improved efficacy of pressurised terbutaline aerosol by use of a 750 ml spacer
222. Evaluation of inhalation aids of metered dose inhalers in asthmatic children
223. Use of a special inhaler attachment in asthmatic children
224. Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. A bioassay using methacholine
225. Efficacy of salbutamol via Easyhaler unaffected by low inspiratory flow
226. Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma
227. Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma
228. Prevention of exercise-induced bronchospasm in pediatric asthma patients: A comparison of two salmeterol powder delivery devices
229. Comparison of Diskus inhaler, a new multidose powder inhaler, with Diskhaler inhaler for the delivery of salmeterol to asthmatic patients. Canadian Study Group
230. Salbutamol powder, administered via a multidose and a single-dose powder inhaler, in the prevention of exercise-induced asthma in children
231. Efficacy and safety of beclomethasone dipropionate (BDP) delivered via a novel dry powder inhaler (Clickhaler) in paediatric patients with asthma
232. Importance of the inhalation device on the effect of budesonide
233. A clinical comparison of beclomethasone dipropionate delivered by pressurised aerosol and as a powder from a Rotahaler
234. Variability of aerosol delivery via spacer devices in young asthmatic children in daily life
235. Drug delivery from the Turbuhaler and Nebuhaler pressurized metered dose inhalers to various age groups of children with asthma
236. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma
237. Diskus and Diskhaler: Efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma
238. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma
239. Asthma medications and how to use them
240. Efficacy of a new non-ozone depleting formulation for salbutamol
241. Clinical comparability of Ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma
242. Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma
243. Proventil HFA prevents exercise-induced bronchoconstriction in children
244. Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma
245. Comparative dose-ranging study of triamcinolone acetonide inhalation aerosol using propellants hydrofluoroalkane 134a or P-12 in children with chronic asthma
246. Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easi-Breathe inhaler for the treatment of paediatric asthma
247. Controlled trial of two formulations of cromolyn sodium in the treatment of asthmatic patients <12 years of age
248. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers
249. Review of therapeutically equivalent alternatives to short acting beta(2) adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers
250. Patient compliance in a clinical trial with inhaled budesonide in children with mild asthma
251. Asthma drug adherence in a long term clinical trial
252. Patient satisfaction with the Diskhaler and the Diskus inhaler, a new multidose powder delivery system for the treatment of asthma
253. Comparison of a new multidose powder inhaler (Diskus/Accuhaler) and the Turbuhaler regarding preference and ease of use
254. Noncompliance and treatment failure in children with asthma
255. Poor inhalation technique, even after inhalation instructions, in children with asthma
256. Treatment adherence among low-income children with asthma
257. Assessment of compliance in children using inhaled beta adrenergic agonists
258. Measurement of children's asthma medication adherence by self report, mother's report, canister weight, and Doser CT
259. Assessment of the ability of young children to use a powder inhaler device (Turbuhaler)
260. Asthma inhaler use and barriers in a population-based sample of African-American and white adolescents
261. Ease of handling and efficacy of Bricanyl Turbuhaler in Asian asthmatics
262. Patient handling of a multidose dry powder inhalation device for albuterol
263. Factors associated with medication self-administration in children with asthma
264. Problems patients have using pressurized aerosols
265. Aerosol inhaler technique in children with asthma
266. Characterization of the inspiratory manoeuvre when asthmatics inhale through a Turbohaler pre- and post-counselling in a community pharmacy
267. Lifestyle changes in mild asthma during intermittent symptom-related use of terbutaline inhaled via Turbohaler
268. An intervention to improve the inhalatory technique of children and adolescents with asthma
269. Evaluation of the Autohaler actuator: The effect of written patient instructions on correct use
270. Errors in inhalation technique and efficiency in inhaler use in asthmatic children
271. Comparison of preference and ease of use of breath-actuated inhalation devices in children
272. Perception among pediatric patients of the Diskus inhaler, a novel multi-dose powder inhaler for use in the treatment of asthma: Comparison with the Turbuhaler inhaler
273. Generic and condition specific outcome measures for people with osteoarthritis of the knee
274. Measuring the health related quality of life in patients with venous leg ulcers
275. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting
276. Health related quality of life of Colles' fracture patients
277. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fracture
278. The role of antileukotrienes in the treatment of chronic asthma. Working Group on Acute Purchasing